8-K current report · filed Oct 16, 2026

IRONWOOD PHARMACEUTICALS INC (IRWD) 8-K Current Report: October 16, 2026

Item 5.02Item EX-99.1IRWD overview

Short answer

IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K current report with the SEC on October 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). CEO succession effective January 1, 2027: Tammi Gaskins replaces Thomas McCourt after his 17 years with Ironwood.

IRONWOOD PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CEO succession effective January 1, 2027: Tammi Gaskins replaces Thomas McCourt after his 17 years with Ironwood
  • Gaskins joins the Board, expanding director count from eight to nine; McCourt remains a director
  • Gaskins compensation: $775,000 base salary, 75% bonus target, approximately $4,000,000 in RSU and PSU target awards
  • McCourt consulting arrangement anticipated at $10,000 monthly after retirement
  • Enhanced severance exposure: 18 months’ salary, or 24 months after a change-of-control termination, plus bonus and benefits давам

Item EX-99.1 · Exhibit EX-99.1

  • Tammi Gaskins becomes CEO and joins the board effective January 1, 2027
  • Tom McCourt retires as CEO after 17 years, remaining on Ironwood’s board
  • Internal succession preserves commercial continuity around LINZESS and apraglutide
  • Gaskins led LINZESS’s turnaround to blockbuster status and growth in 2026
  • Leadership priorities: LINZESS growth, balance-sheet strengthening and Phase 3 STARS-2 apraglutide execution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other IRONWOOD PHARMACEUTICALS INC 8-K filings

Get the next IRWD 8-K as it lands

Follow IRWD for push alerts, or ask the research agent what this filing means.